Publication Name	World Journal of Cardiology
Manuscript ID	85096
Country	United States

Received	2023-04-21 15:43
Peer-Review Started	2023-04-21 15:45
First Decision by Editorial Office Director	2023-06-19 07:31
Return for Revision	2023-06-19 07:31
Revised	2023-07-12 15:10
Publication Fee Transferred
Second Decision by Editor	2023-08-16 02:59
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2023-08-17 01:46
Articles in Press	2023-08-17 01:46
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-09-18 01:44
Publish the Manuscript Online	2023-09-21 08:05

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Retrospective Study
Article Title	Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation
Manuscript Source	Invited Manuscript
All Author List	Chukwuemeka A Umeh, Heather Maoz, Jessica Obi, Ruchi Dakoria, Smit Patel, Gargi Maity and Pranav Barve
ORCID	Author(s) ORCID Number Chukwuemeka A Umeh http://orcid.org/0000-0001-6574-8595 Heather Maoz http://orcid.org/0009-0000-5913-9902 Jessica Obi http://orcid.org/0009-0000-7812-591X Ruchi Dakoria http://orcid.org/0009-0006-9131-919X Smit Patel http://orcid.org/0009-0007-1659-8018 Gargi Maity http://orcid.org/0009-0008-9758-9638 Pranav Barve http://orcid.org/0000-0002-3490-1451
Funding Agency and Grant Number
Corresponding Author	Heather Maoz, MD, Doctor, Doctor, Internal Medicine, Hemet Global Medical Center, 1117 E. Devonshire Ave., Hemet, CA 92543, United States. heathermaoz@gmail.com
Key Words	Coronavirus disease 2019; Troponin elevation; Remdesevir; Ace inhibitor; Steroids
Core Tip	Myocarditis from direct viral injury or related to angiotensin-converting enzyme (ACE) II downregulation with subsequent hyperactivity of the renin-angiotensin-aldosterone system plays an essential role in troponin elevation in coronavirus disease 2019 (COVID-19) patients. However, the effect of antiviral medications and steroids used to treat viral myocarditis has not been well-studied in patients with elevated troponins, which this study sought to address. We found no significant difference in survival rates in COVID-19 patients with elevated troponin that received remdesivir, dexamethasone, or ACE inhibitors vs those that did not. The implication for practice is that treatment with various medications that could be beneficial in viral myocarditis did not show any mortality benefit in our study for COVID-19 patients with troponin elevation.
Publish Date	2023-09-21 08:05
Citation	Umeh CA, Maoz H, Obi J, Dakoria R, Patel S, Maity G, Barve P. Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation. World J Cardiol 2023; 15(9): 427-438
URL	https://www.wjgnet.com/1949-8462/full/v15/i9/427.htm
DOI	https://dx.doi.org/10.4330/wjc.v15.i9.427

Full Article (PDF)	WJC-15-427-with-cover.pdf
Full Article (Word)	WJC-15-427.docx